Click here to read this item in full if you are a subscriber to this newsletter
Our Shopping Cart is currently not working; please phone us on +44 870 1657210 in working hours (08.30 to 18.00 UK time) to place your order or, at other times, please email firstname.lastname@example.org specifying the Publication, Title and Issue date of the item you require.
Issue: November 2009, page: 7
ReGen continues to back knee implant, while US authority reviews own procedures
ReGen Biologics is continuing to market its collagen meniscus implant, trademarked Menaflex, while the US Food and Drug Administration (FDA) reviews its procedural assessment of the process by which the implant received marketing clearance.